Summary of Zhongke Information Conference Call Company Overview - **Company**: Zhongke Information - **Industry**: Brain-Computer Interface (BCI) and Medical Robotics Key Points Industry and Market Potential - The market potential for implanted brain-machine technology in anesthesia robots is estimated to be between **12 billion to 20 billion RMB** (approximately **$1.8 billion to $3 billion**) with a projected **30% penetration rate** [2][4] - The company plans to expand into rehabilitation and pain management sectors, currently conducting trials at the **Wan'an Rehabilitation Hospital** in Tianfu New District [2][4] Product Development and Clinical Trials - Zhongke Information's anesthesia robot has completed **15 clinical trials** successfully, with plans to complete **200 trials** to obtain a Class III medical device certification from the state [2][5] - The company expects to finish clinical trials and submit for certification by the end of this year, aiming for revenue generation by **the second half of 2027** [2][5] Technological Collaboration and Advancements - Collaboration with the **Suzhou Institute of Nano-Tech and Nano-Bionics** has improved the accuracy of EEG signal collection and decoding [3] - Despite being behind **Neuralink** in technology, Zhongke Information is leading in medical rehabilitation applications domestically [3] Revenue Model and Pricing - The expected price for each anesthesia robot is around **1 million RMB** (approximately **$150,000**) [5][7] - Currently, the company employs a unified pricing model for the anesthesia robot, with no established independent pricing standards for its use in rehabilitation hospitals [5][7] Future Directions and Strategic Plans - The company is optimistic about its future, especially with the large-scale production plans of **Neuralink** and the inclusion of brain-machine interfaces in the national **14th Five-Year Plan** [6] - Zhongke Information aims to leverage its advantages as a national technology team and integrate resources from the Chinese Academy of Sciences to achieve breakthroughs in practical applications of brain-like intelligent technology [6] Insurance and Reimbursement Considerations - There is currently no clear indication whether the anesthesia robot will be included in health insurance coverage, and the company is monitoring policy developments closely [7] Additional Important Information - All domestic brain-machine interface products are still in clinical trial phases, with no products having received formal certification yet, indicating that full commercialization will take time [2][4]

Group 1 - China Mobile's Beijing Zhongyi Digital New Economy Industry Fund has become a shareholder in Hefei Zhongke Brain Intelligent Technology Co., Ltd. as of May 27, with registered capital increasing from approximately 14.288 million RMB to about 15.202 million RMB [1] - Hefei Zhongke Brain Intelligent Technology Co., Ltd. was established in September 2017 and focuses on intelligent control system integration, AI public data platforms, AI basic software development, intelligent robotics research, and sales of intelligent unmanned aerial vehicles [1] - The company is now jointly held by Hefei Brain Wisdom Equity Investment Partnership, Liu Haifeng, Hefei Brain Huizhi Equity Investment Partnership, and the newly added shareholder [1] Group 2 - Zhongke Brain specializes in the research and application of brain-like intelligent technology, utilizing core technologies such as computer vision, network intelligence, and cross-media multimodal analysis [1] - The company provides intelligent hybrid cloud platforms and AI solutions [1]

Core Insights - The event marked the third anniversary of the public open day at the Songshan Lake Materials Laboratory, attracting over 1,500 participants, setting a new record for public engagement in science [1] Group 1: Scientific Presentations - Two science reports were presented, including one by researcher Zou Chao on Boron Neutron Capture Therapy (BNCT), a precise cancer treatment method that targets tumor cells using boron-containing drugs [3] - Zou highlighted that BNCT is recognized as "cell-level radiotherapy," utilizing boron-10 isotopes to destroy cancer cells while protecting surrounding healthy tissue [3][5] Group 2: Public Engagement and Interaction - The event featured interactive experiments, allowing participants to engage with various scientific demonstrations, including a showcase of an electric all-terrain vehicle and demonstrations of superconductivity [6] - The public was invited to experience hands-on experiments, emphasizing the importance of engaging children in science from a young age [10] Group 3: Research and Development Focus - The open day showcased several research teams focusing on strategic basic research, industrial applications, and public technology platforms, highlighting advanced domestic equipment such as high-temperature superconducting coating devices [8] - The event included a demonstration of a scanning tunneling microscope capable of observing atoms at a scale of 0.1 nanometers, emphasizing the laboratory's commitment to cutting-edge research [8]